Schering/Enzon collaboration
Executive Summary
Product development and license agreement covers the application of Enzon's proprietary Pegnology drug delivery technology to an undisclosed drug currently marketed by Schering. Enzon uses polyethylene glycol to enhance the half-life of protein-based drugs. One protein-based drug currently marketed by Schering is the recombinant alfa interferon product Intron A.